Compare LONA & MDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LONA | MDAI |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | United States | United States |
| Employees | 19 | 65 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.4M | 77.3M |
| IPO Year | N/A | N/A |
| Metric | LONA | MDAI |
|---|---|---|
| Price | $9.29 | $2.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $10.00 | $3.00 |
| AVG Volume (30 Days) | 36.3K | ★ 976.6K |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $23.50 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.21 | $1.18 |
| 52 Week High | $14.21 | $3.21 |
| Indicator | LONA | MDAI |
|---|---|---|
| Relative Strength Index (RSI) | 47.68 | 44.56 |
| Support Level | $8.10 | $1.78 |
| Resistance Level | $9.88 | $2.80 |
| Average True Range (ATR) | 1.01 | 0.27 |
| MACD | -0.11 | -0.05 |
| Stochastic Oscillator | 33.79 | 18.65 |
LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.
Spectral AI Inc is an AI company focused on predictive medical diagnostics. Its DeepView System uses proprietary AI algorithms to distinguish between fully damaged, partially damaged and healthy human tissue characters invisible to the naked eye, at the initial time point of wound presentation. The DeepView System delivers a binary prediction on the wound's capacity to heal or not-heal by a specified time point in the future. The company focuses on the burn indication which is supported by the BARDA PBS contract.